Cerus Corporation (NASDAQ:CERS) Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in shares of Cerus Corporation (NASDAQ:CERS - Free Report) by 94.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 124,042 shares of the biotechnology company's stock after selling 2,238,388 shares during the period. Bank of America Corp DE owned 0.07% of Cerus worth $191,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Rhumbline Advisers grew its holdings in shares of Cerus by 3.7% in the fourth quarter. Rhumbline Advisers now owns 238,795 shares of the biotechnology company's stock valued at $368,000 after purchasing an additional 8,458 shares during the period. Ieq Capital LLC boosted its holdings in Cerus by 1.2% in the 4th quarter. Ieq Capital LLC now owns 2,169,487 shares of the biotechnology company's stock valued at $3,341,000 after purchasing an additional 26,748 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Cerus by 1.2% in the 4th quarter. Bank of New York Mellon Corp now owns 485,797 shares of the biotechnology company's stock valued at $748,000 after buying an additional 5,721 shares during the period. Los Angeles Capital Management LLC increased its holdings in shares of Cerus by 43.7% during the 4th quarter. Los Angeles Capital Management LLC now owns 280,616 shares of the biotechnology company's stock worth $432,000 after buying an additional 85,392 shares during the last quarter. Finally, ARK Investment Management LLC raised its position in shares of Cerus by 14.2% during the 4th quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company's stock valued at $32,055,000 after buying an additional 2,589,721 shares during the period. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $4.00 price objective on shares of Cerus in a research report on Friday, February 21st.

Cerus Trading Up 2.3%

CERS traded up $0.03 on Thursday, hitting $1.34. The company had a trading volume of 805,385 shares, compared to its average volume of 1,309,213. The company's fifty day moving average price is $1.33 and its 200 day moving average price is $1.54. Cerus Corporation has a 1 year low of $1.12 and a 1 year high of $2.54. The company has a current ratio of 2.32, a quick ratio of 1.63 and a debt-to-equity ratio of 1.15. The firm has a market cap of $256.15 million, a P/E ratio of -13.40 and a beta of 1.55.

Cerus (NASDAQ:CERS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. Cerus had a negative net margin of 10.23% and a negative return on equity of 34.81%. The business had revenue of $43.24 million for the quarter, compared to the consensus estimate of $47.44 million. As a group, equities analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.